gadofluorine M

09/01/2009 - "Gadofluorine-M plaque enhancement may therefore provide functional assessment of atherosclerotic plaque in vivo."
09/01/2009 - "Advanced plaques and early atheroma were enhanced after gadofluorine-M injection. "
01/01/2008 - "Gadofluorine M has been reported to enhance early atherosclerotic plaque signals in magnetic resonance imaging (MRI). "
05/01/2007 - "In combination with high-resolution MRI, Gadofluorine M might enable the detection of thin-cap fibroatheromas, also named the vulnerable plaque."
05/01/2007 - "As previously reported, Gadofluorine M-enhanced magnetic resonance imaging clearly demarcates atherosclerotic plaques from the normal vessel wall. "

05/01/2007 - "Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M."
01/01/2008 - "This preliminary study in rabbits indicated that Gadofluorine M provides specific enhancements of components associated with advanced atherosclerotic plaques and may help to monitor the progression of the plaque in a rabbit model of atherogenesis."
09/01/2009 - "We evaluated gadofluorine-M-enhanced MRI for detection of plaque inflammation and neovascularization in an animal model of atherosclerosis. "
09/01/2009 - "Gadofluorine-M-enhanced MRI is effective for in vivo detection of atherosclerotic plaque inflammation and neovascularization in an animal model of atherosclerosis. "

09/01/2008 - "These unique features of Gadofluorine M in visualizing inflammatory CNS lesions hold promise for future clinical development in multiple sclerosis."
10/18/2010 - "In a longitudinal study we investigated in vivo alterations of CVO during neuroinflammation, applying Gadofluorine M- (Gf) enhanced magnetic resonance imaging (MRI) in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. "
09/01/2008 - "In the present study, application of the experimental magnetic resonance-contrast agent Gadofluorine M significantly increased the sensitivity of lesion detection in myelin-oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis. "

05/01/2012 - "Gadofluorine M-enhanced images provided greater specificity than DWI for identifying LN metastases, whereas the A(z) and sensitivity of the former were comparable to those of the latter."
05/01/2012 - "Two radiologists independently reviewed the DWI set (T2WI, pre-T1WI, DWI) and the gadofluorine M set (T2WI, pre- and post-T1WI) and recorded their confidence scores for LN metastasis on a per-LN basis. "
12/01/2006 - "Gadofluorine M- and MION-47-enhanced MR imaging were performed separately and independently by two radiologists who had no knowledge of histopathologic results, and the presence of metastases in lymph nodes was evaluated. "
05/01/2012 - "To compare the diagnostic performance of a diffusion-weighted imaging (DWI) dataset and a gadofluorine M-enhanced imaging dataset for identifying lymph node (LN) metastases in a rabbit rectal cancer model. "
05/01/2012 - "The area under the receiver operating characteristic curve (AUC) for confidence regarding the presence of metastases in lymph nodes was significantly greater for gadofluorine M than for gadopentetate dimeglumine (AUC, 0.947 vs 0.894; P = .009). "

01/01/2009 - "Gadofluorine M enhancement was significantly greater in skeletal muscle of 30-week-old mice with dysferlin-deficient muscular dystrophy, compared with control mice. "
01/01/2009 - "To compare the usefulness of gadofluorine M with that of Gadomer in assessment of dysferlin-deficient muscular dystrophy at 7.0-T magnetic resonance (MR) imaging. "
01/01/2009 - "Dysferlin-deficient muscular dystrophy: gadofluorine M suitability at MR imaging in a mouse model."
01/01/2009 - "Gadofluorine M-enhanced MR imaging may be of value in monitoring dysferlin-deficient muscular dystrophy disease progression in this animal model and could prove to be a useful tool in following the course of chronic muscle diseases in humans."
01/01/2009 - "SJL/J mice (n = 24) with dysferlin-deficient muscular dystrophy and C57BL/6 control mice (n = 24) were imaged at 12-15 weeks (young) or older than 30 weeks (old) by using dynamic contrast material-enhanced imaging with inversion-prepared steady-state free-precession sequence before, during, and after administration of gadofluorine M at 2 micromol or Gadomer at 4 micromol intravenously. "